Yohei Yabuki

Tokushima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A case of thymic carcinoma harboring an FGFR3 S249C mutation with durable disease control on lenvatinib.

A case of thymic carcinoma harboring an FGFR3 S249C mutation with durable disease control on lenvatinib.

Journal: International cancer conference journal

Published: August 24, 2025

Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody.

Immune checkpoint inhibitor-associated paraneoplastic cerebellar degeneration in a case of extensive-stage small-cell lung cancer with pre-existing anti-SOX1 antibody.

Journal: The journal of medical investigation : JMI

Published: April 23, 2025

A favorable antitumor efficacy of sotorasib in a patient with KRAS G12C-mutated pulmonary large-cell neuroendocrine carcinoma.

A favorable antitumor efficacy of sotorasib in a patient with KRAS G12C-mutated pulmonary large-cell neuroendocrine carcinoma.

Journal: International cancer conference journal

Published: March 04, 2025

Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation.

Clock pathway inhibitor overcomes tumor immune-exclusion via regulation of fibrocyte differentiation.

Journal: NPJ precision oncology

Published: November 04, 2024

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.

Journal: International journal of clinical oncology

Published: June 06, 2024

Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells.

Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells.

Journal: International journal of cancer

Published: May 03, 2024

Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review.

Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review.

Journal: Respiratory medicine case reports

Published: February 05, 2024

Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.

Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.

Journal: Thoracic cancer

Published: September 05, 2023

A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.

A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.

Journal: Thoracic cancer

Published: June 06, 2023

FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.

FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma.

Journal: Respiratory medicine case reports

Published: May 18, 2023

Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.

Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody.

Journal: Respiratory medicine case reports

Published: November 04, 2022

Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.

Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.

Journal: Thoracic cancer

Published: June 27, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026